Try
Pfizer Inc.
PFEUnited States
66 filed reports · 685 financial concepts · 41 earnings calls · 25 media appearances
Filed reports
66 reports · Jul 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 168 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 8,249 | Jul 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 25 | 186 | Dec 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 7,700 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 28, 2026 | Aug 4, 2026 | 6 | Open |
| FY2026 Q2 | 10-Q | Jun 28, 2026 | Aug 4, 2026 | 551 | Open |
| FY2026 Q1 | 8-K | Mar 29, 2026 | May 5, 2026 | 6 | Open |
| FY2026 Q1 | 10-Q | Mar 29, 2026 | May 5, 2026 | 366 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 1,433 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 3, 2026 | 6 | Open |
| FY2025 Q3 | 10-Q | Sep 28, 2025 | Nov 4, 2025 | 368 | Open |
| FY2025 Q3 | 8-K | Sep 28, 2025 | Nov 4, 2025 | 6 | Open |
| FY2025 Q2 | 10-Q | Jun 29, 2025 | Aug 5, 2025 | 234 | Open |
| FY2025 Q2 | 8-K | Jun 29, 2025 | Aug 5, 2025 | 6 | Open |
| FY2025 Q1 | 10-Q | Mar 30, 2025 | May 5, 2025 | 231 | Open |
| FY2025 Q1 | 8-K | Mar 30, 2025 | Apr 29, 2025 | 6 | Open |
Financial data
685 concepts · 16,135 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial637 concepts · 14,595 facts · Dec 2014 to Jul 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Amortization of intangible assets57 · Dec 2014 to Jun 2026
- Asset impairments57 · Dec 2014 to Jun 2026
- Business exit costs157 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax attributable to noncontrolling interest57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest57 · Dec 2014 to Jun 2026
- Cost of sales57 · Dec 2014 to Jun 2026
- Defined benefit plan amounts recognized in other comprehensive income net prior service cost credit before tax57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Interest expense (US GAAP)57 · Dec 2014 to Jun 2026
- Interest revenue expense net57 · Dec 2014 to Jun 2026
- Investment income interest57 · Dec 2014 to Jun 2026
- Net income loss57 · Dec 2014 to Jun 2026
- Net income loss attributable to noncontrolling interest57 · Dec 2014 to Jun 2026
- Net income loss available to common stockholders basic57 · Dec 2014 to Jun 2026
- Net income loss available to common stockholders diluted57 · Dec 2014 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss before reclassification and tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss amortization adjustment from AOCI pension and other postretirement benefit plans for net prior service cost credit before tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss amortization adjustment from AOCI pension and other postretirement benefit plans for net prior service cost credit tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment before tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss available for sale securities tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss before tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss foreign currency translation adjustment tax57 · Dec 2014 to Jun 2026
Segment16 concepts · 778 facts · Dec 2014 to Jun 2026
- Revenue307 · Dec 2014 to Jun 2026
- Restructuring charges86 · Dec 2014 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest79 · Dec 2014 to Jun 2026
- Revenue (excluding assessed tax)60 · Dec 2017 to Sep 2020
- Goodwill46 · Dec 2015 to Sep 2020
- Goodwill other increase decrease46 · Dec 2015 to Jun 2020
- Depreciation depletion and amortization32 · Dec 2014 to Jun 2026
- Goodwill acquired during period23 · Dec 2015 to Dec 2019
- Impairment of intangible assets excluding goodwill21 · Dec 2014 to Dec 2025
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- Other nonoperating income expense14 · Dec 2022 to Jun 2026
- Research and development asset acquired other than through business combination written off14 · Dec 2022 to Jun 2026
- Research and development expense excluding acquired in process cost14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Paxlovid5 · Mar 2024 to Dec 2024
- Costs and expenses3 · Jun 2015 to Apr 2016
Geography6 concepts · 393 facts · Dec 2014 to Jun 2026
- Revenue248 · Dec 2014 to Jun 2026
- U.S.98 · Jul 2016 to Sep 2024
- Property, Plant & Equipment, Net43 · Dec 2015 to Dec 2025
- Venezuela2 · Dec 2015
- Production related impairments or charges1 · Oct 2017
- Restructuring charges1 · Dec 2015
Guidance17 concepts · 186 facts · Feb 2021 to Aug 2026
- Revenue Guidance48 · Feb 2021 to Aug 2026
- EPS (Diluted) Guidance42 · Jul 2021 to Aug 2026
- Effective Tax Rate Guidance40 · Jul 2021 to Aug 2026
- Revenue Growth Guidance12 · May 2021 to Oct 2024
- Effective Tax Rate Guidance (Adjusted (non-GAAP))8 · Feb 2021 to Jan 2024
- EPS (Diluted) Guidance (Adjusted (non-GAAP))8 · Feb 2021 to Jan 2024
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))4 · May 2021 to Nov 2021
- EPS (Diluted) Guidance (Excluding BNT162b2; Adjusted (non-GAAP))4 · Feb 2021 to May 2021
- Revenue Guidance (Excluding BNT162b2)4 · Feb 2021 to May 2021
- EPS (Diluted) Growth Guidance (excluding BNT162b2; Adjusted, constant currency)2 · May 2021
- EPS (Diluted) Growth Guidance (excluding Comirnaty(1); Adjusted, constant currency)2 · Nov 2021
- EPS (Diluted) Guidance (excluding Comirnaty(1); Adjusted (non-GAAP))2 · Nov 2021
- Revenue Growth Guidance (excluding BNT162b2; Constant currency)2 · May 2021
- Revenue Growth Guidance (excluding Comirnaty(1); Constant currency)2 · Nov 2021
- Revenue Growth Guidance (Excluding revenues from Comirnaty(1) and Paxlovid and the expected contribution from Seagen; Constant currency)2 · Jan 2024
- Revenue Growth Guidance (Including the contribution from Seagen and excluding revenues from Comirnaty(1) and Paxlovid; Constant currency)2 · Jan 2024
- Revenue Guidance (excluding Comirnaty(1))2 · Nov 2021
Product9 concepts · 183 facts · Dec 2014 to Jun 2026
- Revenue109 · Dec 2018 to Jun 2026
- Revenue (excluding assessed tax)24 · Jul 2017 to Dec 2021
- Revenue from collaborative arrangement excluding revenue from contract with customer24 · Dec 2020 to Jun 2026
- Inventory write down6 · Dec 2023
- Paxlovid6 · Mar 2024 to Mar 2025
- Royalty revenue6 · Dec 2016 to Dec 2017
- Gain loss related to litigation settlement5 · Dec 2014 to Oct 2021
- Impairment of intangible assets excluding goodwill2 · Dec 2023
- Royalty income nonoperating1 · Dec 2017
Segments
1,354 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments19 members · 722 facts
- Biopharma223 · Dec 2017 to Jun 2026
- Innovative Healthand Essential Health94 · Dec 2014 to Dec 2018
- Essential Health92 · Dec 2014 to Dec 2018
- Innovative Health90 · Dec 2014 to Dec 2018
- Upjohn47 · Dec 2017 to Sep 2020
- Biopharma upjohn and consumer healthcare segments42 · Apr 2018 to Sep 2020
- Business Innovation36 · Dec 2021 to Mar 2024
- Pfizer Centre One18 · Dec 2019 to Sep 2024
- Essential health segment15 · Dec 2015 to Dec 2018
- Innovative health segment15 · Dec 2015 to Dec 2018
- Upjohn segment9 · Dec 2018 to Sep 2020
- Innovative healthand essential health8 · Dec 2017 to Dec 2018
- Pfizer centre one segment8 · Apr 2018 to Sep 2020
- Biopharma segment7 · Jun 2019 to Sep 2020
- Pfizer centre one6 · Dec 2018 to Apr 2023
- Pfizer Ignite4 · Jul 2023 to Sep 2024
- Biopharma And Upjohn3 · Apr 2018 to Sep 2018
- Consumer Healthcare3 · Dec 2018 to Dec 2019
- Pfizer ignite2 · Jul 2022 to Apr 2023
Statement geographicalsrt:StatementGeographicalAxis9 members · 265 facts
- US67 · Dec 2016 to Jun 2026
- Developed Europe51 · Dec 2016 to Dec 2023
- Developed Rest Of World49 · Dec 2016 to Dec 2023
- Emerging Markets49 · Dec 2016 to Dec 2023
- International Developed Markets21 · Dec 2022 to Jun 2026
- International Emerging Markets21 · Dec 2022 to Jun 2026
- Developed markets3 · Dec 2023 to Dec 2025
- International emerging markets3 · Dec 2023 to Dec 2025
- PR1 · Oct 2017
Product or servicesrt:ProductOrServiceAxis20 members · 174 facts
- Total Alliance Biopharmaceuticals39 · Dec 2018 to Jun 2026
- Product18 · Dec 2022 to Jun 2026
- Royalty18 · Dec 2022 to Jun 2026
- Pfizer Centre One14 · Dec 2022 to Jun 2026
- Total Biosimilars14 · Dec 2018 to Jul 2022
- Total Sterile Injectable Pharmaceuticals14 · Dec 2018 to Jul 2022
- Pfizer Ignite12 · Dec 2022 to Dec 2025
- Total alliance biopharmaceuticals10 · Jul 2017 to Sep 2019
- Paxlovid EUA Labeled8 · Dec 2023 to Mar 2025
- Total biosimilars5 · Sep 2018 to Sep 2019
- Total sterile injectable pharmaceuticals5 · Sep 2018 to Sep 2019
- Product4 · Dec 2018 to Dec 2021
- Paxlovid NDA Labeled US Strategic National Stockpile3 · Sep 2024 to Dec 2024
- Comirnaty2 · Dec 2023
- Epi Pen2 · Jul 2021 to Oct 2021
- Paxlovid And Comirnaty2 · Dec 2023
- Etrasimod Velsipity1 · Dec 2023
- Pfizer ignite1 · Dec 2022
- Prevnar131 · Dec 2023
- Xtandi1 · Dec 2017
Statement geographicalus-gaap:StatementGeographicalAxis9 members · 128 facts
- Developed Europe22 · Dec 2014 to Apr 2018
- Developed Rest Of World22 · Dec 2014 to Apr 2018
- Emerging Markets22 · Dec 2014 to Apr 2018
- US22 · Dec 2014 to Apr 2018
- Us11 · Dec 2015 to Dec 2025
- Developed europe9 · Dec 2015 to Dec 2023
- Developed rest of world9 · Dec 2015 to Dec 2023
- Emerging markets8 · Dec 2015 to Dec 2023
- VE3 · Dec 2015
Subsegments7 members · 56 facts
- U.S. Commercial Division18 · Dec 2022 to Jun 2026
- International Commercial Division17 · Dec 2022 to Jun 2026
- Oncology Division11 · Dec 2022 to Dec 2024
- Global Hospital And Biosimilars Division4 · Mar 2025 to Jun 2026
- Consumer Healthcare2 · Dec 2014 to Dec 2015
- International Division2 · Apr 2023 to Mar 2024
- Pfizers Worldwide Researchand Development2 · Dec 2014 to Dec 2015
Product or serviceus-gaap:ProductOrServiceAxis4 members · 9 facts
- Xtandi6 · Dec 2016 to Dec 2017
- Effexor1 · Dec 2014
- Neurontin1 · Dec 2014
- Protonix Pantoprazole1 · Dec 2015
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary149 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary72 claims from 4 reports · Dec 2024 to Jun 2026
- Risk-factor changes11 claims from 1 reports · Dec 2025
- Risk factors46 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · May 2016 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1May 5, 2026
- FY2025 Q4Feb 3, 2026
- FY2025 Q3Nov 4, 2025
- FY2025 Q2Aug 5, 2025
- FY2025 Q1Apr 29, 2025
- FY2024 Q4Feb 4, 2025
- FY2024 Q3Oct 29, 2024
- FY2024 Q2Jul 30, 2024
- FY2024 Q1May 1, 2024
- FY2023 Q4Jan 30, 2024
- FY2023 Q3Oct 31, 2023
- FY2023 Q2Aug 1, 2023
- FY2023 Q1May 2, 2023
- FY2022 Q4Jan 31, 2023
- FY2022 Q3Nov 1, 2022
Executive media
25 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances11 · Aug 2020 to May 2026
- TV interviews10 · Dec 2020 to Jan 2026
- Podcasts3 · Dec 2021 to May 2026
- Conference talks1 · Jul 2022
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.